Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow EXACT SCIENCES CORP

Get SEC filing alerts via email and in your feed for EXACT SCIENCES CORP

EXAS

EXACT SCIENCES CORP

About EXACT SCIENCES CORP

Exact Sciences Corporation specializes in cancer screening and diagnostic tests, including non-invasive stool-based and blood-based assays, as well as precision oncology genomic profiling. Its core products, such as Cologuard and Oncotype DX, serve healthcare providers and patients worldwide, offering early detection, personalized treatment insights, and improved clinical outcomes. The company’s business model emphasizes innovation, regulatory approval, reimbursement strategies, and global commercialization in the rapidly evolving molecular diagnostics industry.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from EXACT SCIENCES CORP

1
1
EXACT SCIENCES CORP Exact Sciences Corporation Reports $3.25 Billion Revenue and Merger Agreement with Abbott Laboratories

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
EXACT SCIENCES CORP Exact Sciences Reports 20% Revenue Growth to $850.7 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
EXACT SCIENCES CORP Exact Sciences Reports 16% Revenue Growth to $811.1 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
EXACT SCIENCES CORP Exact Sciences Reports $706.8 Million Revenue in Q1 2025, Driven by Screening Growth

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
EXACT SCIENCES CORP Exact Sciences Reports $2.76 Billion Revenue with 10% Growth, Faces $1.03 Billion Net Loss

Via official filing (AI summary) | over 1 year ago | 0 comments

6
1
EXACT SCIENCES CORP Exact Sciences Reports 13% Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments